Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 3/20 | 0.41 |
| ▸ | BCL6 | P41182 | 3/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22125118 | 1.00 | PTK6 (0.41) | PTK6BCL6P2RX3LRRK2PDE5A | |
| SCHEMBL24112594 | 0.90 | PTK6 (0.41) | PTK6BCL6PDE5APOLBALK | |
| SCHEMBL22124504 | 0.90 | PTK6 (0.42) | PTK6BCL6LRRK2TTKALK | |
| SCHEMBL24112398 | 0.90 | PTK6 (0.44) | PTK6BCL6POLBLCKTTK | |
| SCHEMBL24112596 | 0.90 | PTK6 (0.40) | PTK6BCL6P2RX3LRRK2PDE5A | |
| SCHEMBL25450750 | 0.90 | PTK6 (0.42) | PTK6BCL6LRRK2LCKTTK | |
| SCHEMBL22123532 | 0.90 | PTK6 (0.42) | PTK6BCL6LRRK2PDE5ATTK | |
| SCHEMBL22123365 | 0.90 | PTK6 (0.42) | PTK6BCL6LRRK2PDE5ATTK | |
| SCHEMBL22123658 | 0.90 | PTK6 (0.42) | PTK6BCL6LRRK2PDE5ATTK | |
| Hydrochloric Acid SCHEMBL30171699 | 0.90 | PTK6 (0.42) | PTK6BCL6LRRK2TTKALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2141/4885BCL6 3737/4885P2RX3 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.